Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 55 citing articles:

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 244
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection
Daping Yang, Amanda Jacobson, Kimberly A. Meerschaert, et al.
Cell (2022) Vol. 185, Iss. 22, pp. 4190-4205.e25
Open Access | Times Cited: 120
Hallmarks of primary headache: part 1 – migraine
Alberto Raggi, Matilde Leonardi, Marco A. Arruda, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 27
Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
Wenfang Sun, Yali Li, Binbin Xia, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor
Gabriel Gárate, Vicente González‐Quintanilla, Andrea González, et al.
Annals of Neurology (2023) Vol. 94, Iss. 2, pp. 285-294
Open Access | Times Cited: 22
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
Bianca Raffaelli, Roberto De Icco, Michele Corrado, et al.
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 15
Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models
Shafaqat M. Rahman, Anne E. Luebke
Cephalalgia (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 5
Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
Michał Fila, Jan Chojnacki, Piotr Sobczuk, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 289-289
Open Access | Times Cited: 11
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine
Francesco Saccà, Simone Braca, Mattia Sansone, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 6, pp. 788-794
Open Access | Times Cited: 11
Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
Qi Wang, Jingfang Liu, Hao Sun, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 107-117
Open Access | Times Cited: 11
Potential benefits and possible risks of CGRP-targeted multitherapy in migraine
Keiko Ihara, Tsubasa Takizawa, Narumi Watanabe, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 1-2, pp. 1-4
Open Access | Times Cited: 4
Efficacy and Safety of Switching Between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review
Kota Oshima, Keiko Ihara, Narumi Watanabe, et al.
Internal Medicine (2025)
Open Access
Fremanezumab for refractory migraine in patients with hereditary transthyretin amyloidosis: A case series
Joana Fernandes, Sofia Ferreira, Cristina Alves, et al.
Cephalalgia Reports (2025) Vol. 8
Open Access
Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
Mohamed E. Haseeb, Hazem E. Mohammed, Hatem Yaser, et al.
Head & Face Medicine (2025) Vol. 21, Iss. 1
Open Access
Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system
Nai Lee, Jihoon Ok, Yonghoon Kwon, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Neurotransmitter and neuropeptide regulation of gut immunity
Calvin Wong, Isaac M. Chiu
Current Opinion in Neurobiology (2025) Vol. 92, pp. 103036-103036
Closed Access
The evolving concept of multimorbidity and migraine
Claudia Altamura, Gianluca Coppola, Fabrizio Vernieri
Handbook of clinical neurology (2024), pp. 535-566
Closed Access | Times Cited: 3
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
Simona Guerzoni, Carlo Baraldi, Flavia Lo Castro, et al.
Brain and Behavior (2023) Vol. 13, Iss. 6
Open Access | Times Cited: 9
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation
Ning Wei, Ge Gao, Yong Zhou, et al.
International Immunopharmacology (2023) Vol. 116, pp. 109747-109747
Closed Access | Times Cited: 8
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor
Sanne Hage la Cour, Kiki Juhler, Lisette J. A. Kogelman, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Single Nucleus Sequencing of Human Colon Myenteric Plexus–Associated Visceral Smooth Muscle Cells, Platelet Derived Growth Factor Receptor Alpha Cells, and Interstitial Cells of Cajal
Sabine Schneider, S. Hashmi, A. Josephine Thrasher, et al.
Gastro Hep Advances (2022) Vol. 2, Iss. 3, pp. 380-394
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top